QSI

Quantum-Si

QSI

Attention (50-day avg)0%

Attention rank (50-day avg)#1,331

Bullish sentiment (50-day avg)50%

Price to earnings ratio-1.58

Market capitalization174M

Earnings per share-0.46

Dividend yield (TTM)—

Revenue (annual)2.4M

Net income (annual)-101.3M

Social

What share of all stock conversation is about QSI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.02	0% +0	0% +0	0% -0.02

Sep 29

The company is expected to embark on a Proteus Roadshow circuit in Europe, which could lead to increased visibility and a positive impact on the stock price.
The stock has seen a significant increase in volume, with 5x the 10-day average volume in just 90 minutes into the trading session.
A recent report from HC Wainwright reiterated a buy rating with a price target of $4, and the company's cash runway is expected to last until Q4 2028.

Generated by AI

Sentiment

Of the messages about QSI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	82.3%	82.68% -17.32	39.04% -39.79	93.32% +3.64
Bearish	17.7%	17.32% +17.32	60.96% +39.79	6.68% -3.64

Bullish· Sep 29

The company's cash runway is expected to last until Q4 2028, providing a long-term financial foundation for growth.
The product launch in Q2 2027 is anticipated to be a major catalyst for the company's stock price, with many investors expecting a significant move in the next 6 months leading up to the launch.
The company has no debt, and recent buy recommendations from HC Wainwright, including a price target of $4.00, further support the stock's bullish sentiment.

Bearish· Sep 29

$QSI's massive short position and failed product launch are significant bearish concerns, with the company's revenue dropped 42% and no future revenue in sight.
The company's $300 million shelf offering is likely to result in a significant dilution, which will be a major hit to the stock price.
$QSI's strong downtrend since October 25, with a 70c target in the next week, and its failed to launch product and postponed product release day to Q2 2027 are all bearish indicators.

Generated by AI

Topics

Of the messages about QSI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	27.27%	23.08%	4.04%	2.51%
Technical Analysis	0%	61.54%	53.59%	5.63%
Controversies	0%	0%	0%	0%
Analysts	72.73%	15.38%	1.79%	40.67%
Macro	0%	0%	40.58%	41.21%
Earnings	0%	0%	0%	9.97%

Announcements· Feb 6

Two independent research groups published papers using Quantum-Si's benchtop protein sequencing platform, one in the Journal of Analytical Chemistry demonstrating direct identification of clinically relevant hemoglobin variants from real blood samples.
A peer-reviewed paper showed the system can directly identify clinically relevant hemoglobin variants from real blood samples, which is a significant advancement in clinical proteomics.
The company has broad ownership, with approximately 38% retail ownership, and the management monitors retail message boards to address questions and concerns from retail holders.

Technical Analysis· Oct 16

$QSI is expected to run hard today with increasing volume, potentially breaking out to 3.10-3.50.
The stock's MACD is currently bullish, with a sharp divergence above the signal line, but it's close to overbought territory.
$QSI's primary support is at 2.5$, with a possible breakout above 3.50 triggering gamma, and the stock is expected to take multiple attempts to break and hold $3.

Generated by AI

Community

Of the messages about QSI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	60.27%	57.76%	72.38%	53.15%
Newcomers	39.73%	42.24%	27.62%	46.85%

Regulars· Sep 29

Quantum-Si's Proteus Roadshow in Europe is gaining momentum, with the company set to embark on the tour and potentially increase awareness of its technology.
The company's Proteus platform has demonstrated a significant step change in performance compared to its commercially available Platinum Pro instrument, outperforming it in every key measure.
Quantum-Si's stock price is experiencing significant gains, with the stock price already at $1 and some users predicting it will reach $2 or more, while others are focusing on the company's potential for a cure for cancer.

Newcomers· Sep 29

Many newcomers are excited about Quantum-Si's long cash runway, with some expecting a major move in the next 6 months leading up to the product launch in Q2 2027.
Some new investors are focused on the potential for a significant price increase, with one user estimating a 5x potential in the stock.
Others are calling out short sellers, suggesting that the stock is undervalued and that the bears will be proved wrong.

Generated by AI

News

Why Is Quantum-Si Stock Gaining Tuesday? - Quantum-Si (NASDAQ:QSI)

Quantum-Si (QSI) stock jumped over 24% after presenting impressive interim Proteus platform data at the HUPO 2026 conference.

18h agoBenzinga

Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro

All measurable sequencing metrics show profound improvement over Platinum ProBRANFORD, Conn., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Quantum-Si Incorporated (Nasdaq: QSI) (“Quantum-Si,” “QSI” or the “Company”), a proteomics company redefining protein analysis through single-molecule protein sequencing, today announced interim development results comparing its next-generation Proteus™ platform with its commercially available Platinum® Pro instrument. Using a developmental sequencing kit that detects

1d agoYahoo Finance

Also Discussed

Investors talking about QSI also mention

#	Name	Attention
1	Quantum Computing Inc.QUBT	0%-0.01
2	Butterfly Network, Inc.BFLY	0.01%0
3	OLK - Olink Holding AB (publ)	——
4	Rigetti Computing, Inc.RGTI	0.01%-0.01
5	SEALSQ CorpLAES	0%0
6	D-Wave Quantum Inc.QBTS	0%-0.01
7	Hyperfine, Inc. Class A Common StockHYPR	0%0
8	Seer, Inc. Class A Common StockSEER	0%0
9	Quantum CorporationQMCO	0%0
10	IonQ, Inc.IONQ	0.11%-0.08

Quantum-Si Incorporated Class A Common Stock

Healthcare
Medical Devices

Quantum-Si Incorporated Class A Common Stock represents ownership in Quantum-Si Incorporated, a life sciences company focused on proteomics and single-molecule protein analysis. Quantum-Si develops benchtop instrumentation, consumables, and software designed to support next-generation protein sequencing and automated protein data interpretation. Its current product set includes the Platinum and Platinum Pro instruments, library preparation kits, sequencing kits, and analysis software used in protein identification, protein variant detection, biomarker research, antibody characterization, and post-translational modification analysis. The company serves research laboratories and scientific organizations that need tools for detailed protein-level investigation. Quantum-Si Incorporated Class A Common Stock reflects a market position tied to specialized biotechnology research tools and the broader demand for advanced protein analysis technologies in the life sciences sector.

Website

Location

29 Business Park Drive

Branford, CT, 06405

United States

Social

What share of all stock conversation is about QSI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.02% +0.02	0% +0	0% +0	0% -0.02

Sep 29

The company is expected to embark on a Proteus Roadshow circuit in Europe, which could lead to increased visibility and a positive impact on the stock price.
The stock has seen a significant increase in volume, with 5x the 10-day average volume in just 90 minutes into the trading session.
A recent report from HC Wainwright reiterated a buy rating with a price target of $4, and the company's cash runway is expected to last until Q4 2028.

Generated by AI

Sentiment

Of the messages about QSI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	82.3%	82.68% -17.32	39.04% -39.79	93.32% +3.64
Bearish	17.7%	17.32% +17.32	60.96% +39.79	6.68% -3.64

Bullish· Sep 29

The company's cash runway is expected to last until Q4 2028, providing a long-term financial foundation for growth.
The product launch in Q2 2027 is anticipated to be a major catalyst for the company's stock price, with many investors expecting a significant move in the next 6 months leading up to the launch.
The company has no debt, and recent buy recommendations from HC Wainwright, including a price target of $4.00, further support the stock's bullish sentiment.

Bearish· Sep 29

$QSI's massive short position and failed product launch are significant bearish concerns, with the company's revenue dropped 42% and no future revenue in sight.
The company's $300 million shelf offering is likely to result in a significant dilution, which will be a major hit to the stock price.
$QSI's strong downtrend since October 25, with a 70c target in the next week, and its failed to launch product and postponed product release day to Q2 2027 are all bearish indicators.

Generated by AI

Topics

Of the messages about QSI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	27.27%	23.08%	4.04%	2.51%
Technical Analysis	0%	61.54%	53.59%	5.63%
Controversies	0%	0%	0%	0%
Analysts	72.73%	15.38%	1.79%	40.67%
Macro	0%	0%	40.58%	41.21%
Earnings	0%	0%	0%	9.97%

Announcements· Feb 6

Two independent research groups published papers using Quantum-Si's benchtop protein sequencing platform, one in the Journal of Analytical Chemistry demonstrating direct identification of clinically relevant hemoglobin variants from real blood samples.
A peer-reviewed paper showed the system can directly identify clinically relevant hemoglobin variants from real blood samples, which is a significant advancement in clinical proteomics.
The company has broad ownership, with approximately 38% retail ownership, and the management monitors retail message boards to address questions and concerns from retail holders.

Technical Analysis· Oct 16

$QSI is expected to run hard today with increasing volume, potentially breaking out to 3.10-3.50.
The stock's MACD is currently bullish, with a sharp divergence above the signal line, but it's close to overbought territory.
$QSI's primary support is at 2.5$, with a possible breakout above 3.50 triggering gamma, and the stock is expected to take multiple attempts to break and hold $3.

Generated by AI

Community

Of the messages about QSI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	60.27%	57.76%	72.38%	53.15%
Newcomers	39.73%	42.24%	27.62%	46.85%

Regulars· Sep 29

Quantum-Si's Proteus Roadshow in Europe is gaining momentum, with the company set to embark on the tour and potentially increase awareness of its technology.
The company's Proteus platform has demonstrated a significant step change in performance compared to its commercially available Platinum Pro instrument, outperforming it in every key measure.
Quantum-Si's stock price is experiencing significant gains, with the stock price already at $1 and some users predicting it will reach $2 or more, while others are focusing on the company's potential for a cure for cancer.

Newcomers· Sep 29

Many newcomers are excited about Quantum-Si's long cash runway, with some expecting a major move in the next 6 months leading up to the product launch in Q2 2027.
Some new investors are focused on the potential for a significant price increase, with one user estimating a 5x potential in the stock.
Others are calling out short sellers, suggesting that the stock is undervalued and that the bears will be proved wrong.

Generated by AI

Quantum-Si

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Announcements· Feb 6

Technical Analysis· Oct 16

Regulars· Sep 29

Newcomers· Sep 29

Why Is Quantum-Si Stock Gaining Tuesday? - Quantum-Si (NASDAQ:QSI)

Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro

Quantum-Si CEO Jeffrey Hawkins sells $22,610 in stock

Quantum-Si CFO Jeffry Keyes sells $5,805 in company stock

Quantum-Si GC LaPointe sells $10,994 in shares for tax withholding

Quantum-Si demonstrates detection of 18 amino acids on Proteus

Also Discussed

Quantum-Si Incorporated Class A Common Stock

Company Information

Location

Why Is Quantum-Si Stock Gaining Tuesday? - Quantum-Si (NASDAQ:QSI)

Quantum-Si Presents Interim Proteus™ Data at World HUPO 2026 Demonstrating a Significant Step Change in Performance Compared to Platinum® Pro

Quantum-Si CEO Jeffrey Hawkins sells $22,610 in stock

Quantum-Si CFO Jeffry Keyes sells $5,805 in company stock

Quantum-Si GC LaPointe sells $10,994 in shares for tax withholding

Quantum-Si demonstrates detection of 18 amino acids on Proteus

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Announcements· Feb 6

Technical Analysis· Oct 16

Regulars· Sep 29

Newcomers· Sep 29